171 related articles for article (PubMed ID: 34039301)
21. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model.
Berdy GJ; Stoppel JO; Epstein AB
Clin Ther; 2002 Jun; 24(6):918-29. PubMed ID: 12117082
[TBL] [Abstract][Full Text] [Related]
22. Loteprednol etabonate gel 0.5% vs prednisolone acetate suspension 1% for the treatment of inflammation after cataract surgery in children.
Vittitow JL; Williams JI
J Cataract Refract Surg; 2020 Aug; 46(8):1092-1101. PubMed ID: 32352250
[TBL] [Abstract][Full Text] [Related]
23. [The observation of tacrolimus eye drops preventing the early immunological rejection after penetrating keratoplasty for fungal keratitis].
Xiang DM; Wang YX; Jia YN; Li SX; Zhai HL; Shi WY; Gao H
Zhonghua Yan Ke Za Zhi; 2017 Apr; 53(4):305-310. PubMed ID: 28412805
[No Abstract] [Full Text] [Related]
24. Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers.
Holland EJ; Bartlett JD; Paterno MR; Usner DW; Comstock TL
Cornea; 2008 Jan; 27(1):50-5. PubMed ID: 18245967
[TBL] [Abstract][Full Text] [Related]
25. Incidence and Risk Factors of Elevated Intraocular Pressure Following Deep Anterior Lamellar Keratoplasty.
Huang OS; Mehta JS; Htoon HM; Tan DT; Wong TT
Am J Ophthalmol; 2016 Oct; 170():153-160. PubMed ID: 27519560
[TBL] [Abstract][Full Text] [Related]
26. Randomized clinical trial of deep lamellar keratoplasty vs penetrating keratoplasty.
Shimazaki J; Shimmura S; Ishioka M; Tsubota K
Am J Ophthalmol; 2002 Aug; 134(2):159-65. PubMed ID: 12140020
[TBL] [Abstract][Full Text] [Related]
27. Safety of KPI-121 Ophthalmic Suspension 0.25% in Patients With Dry Eye Disease: A Pooled Analysis of 4 Multicenter, Randomized, Vehicle-Controlled Studies.
Korenfeld M; Nichols KK; Goldberg D; Evans D; Sall K; Foulks G; Coultas S; Brazzell K
Cornea; 2021 May; 40(5):564-570. PubMed ID: 32826644
[TBL] [Abstract][Full Text] [Related]
28. [Clinical features of glucocorticoid eye drops induced ocular hypertension in pediatric and adult uveitic eyes].
Pei MH; Zhao C; Gao F; Zhang MF
Zhonghua Yan Ke Za Zhi; 2018 Nov; 54(11):839-842. PubMed ID: 30440155
[No Abstract] [Full Text] [Related]
29. Loteprednol etabonate: clinical potential in the management of ocular inflammation.
Noble S; Goa KL
BioDrugs; 1998 Oct; 10(4):329-39. PubMed ID: 18020605
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of long-term corticosteroid eye drops after penetrating keratoplasty: a prospective, randomized, clinical trial.
Shimazaki J; Iseda A; Satake Y; Shimazaki-Den S
Ophthalmology; 2012 Apr; 119(4):668-73. PubMed ID: 22264885
[TBL] [Abstract][Full Text] [Related]
31. Intraocular pressure response to loteprednol etabonate in known steroid responders.
Bartlett JD; Horwitz B; Laibovitz R; Howes JF
J Ocul Pharmacol; 1993; 9(2):157-65. PubMed ID: 8345288
[TBL] [Abstract][Full Text] [Related]
32. A retrospective study comparing DALK and PKP in the treatment of necrotizing stromal keratitis.
Liu H; Liu S; Tao H; Hu S; Deng Z; Tan J
Int Ophthalmol; 2020 Jul; 40(7):1713-1721. PubMed ID: 32207047
[TBL] [Abstract][Full Text] [Related]
33. [Study on the treatment of dry eye with Loteprednol Etabonate].
Wan PX; Wang XR; Song YY; Li ZY; Duan HC; Zhang W; Liu Z; Wang ZC
Zhonghua Yan Ke Za Zhi; 2012 Feb; 48(2):142-7. PubMed ID: 22490950
[TBL] [Abstract][Full Text] [Related]
34. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
Abelson M; Howes J; George M
J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336
[TBL] [Abstract][Full Text] [Related]
35. Long-term comparison of full-bed deep lamellar keratoplasty with penetrating keratoplasty in treating corneal leucoma caused by herpes simplex keratitis.
Wu SQ; Zhou P; Zhang B; Qiu WY; Yao YF
Am J Ophthalmol; 2012 Feb; 153(2):291-299.e2. PubMed ID: 21996306
[TBL] [Abstract][Full Text] [Related]
36. Dose uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%).
Marlowe ZT; Davio SR
Clin Ophthalmol; 2014; 8():23-9. PubMed ID: 24357925
[TBL] [Abstract][Full Text] [Related]
37. Comparison between Betamethasone, Fluorometholone and Loteprednol Etabonate on intraocular pressure in patients after keratorefractive surgery.
Shokoohi-Rad S; Daneshvar R; Jafarian-Shahri M; Rajaee P
J Curr Ophthalmol; 2018 Jun; 30(2):130-135. PubMed ID: 29988925
[TBL] [Abstract][Full Text] [Related]
38. Is there a role for tapered topical dose steroidal treatment for dry eye disease? A randomized, pilot study.
Barabino S; Montaldo E; Mingari MC; Mazzotta C; Giuffrida S; Rolando M
Eur J Ophthalmol; 2022 Jul; 32(4):2452-2458. PubMed ID: 34585595
[TBL] [Abstract][Full Text] [Related]
39. Loteprednol etabonate: a formulation for short-term use in inflammatory flares in dry eye disease.
Paton DM
Drugs Today (Barc); 2022 Feb; 58(2):77-84. PubMed ID: 35188142
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of deep anterior lamellar keratoplasty vs. penetrating keratoplasty for keratoconus: a meta-analysis.
Liu H; Chen Y; Wang P; Li B; Wang W; Su Y; Sheng M
PLoS One; 2015; 10(1):e0113332. PubMed ID: 25633311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
